12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Amyvid florbetapir regulatory update

CMS' Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) concluded there is inadequate evidence to determine whether beta amyloid PET imaging can change health outcomes in patients who display early symptoms of cognitive dysfunction. The average vote of the 12 voting committee members was 2.2 on a scale of 1-5, where 1 is "low confidence" and 5 is "high confidence."

The committee met to discuss...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >